Amyloidosis is a systemic disease characterized by extracellular deposition of insoluble fibrils [1]. Cardiac amyloidosis (CA) is common in both immunoglobulin light-chain (AL) and transthyretin amyloidosis (ATTR), and usually manifests with signs and symptoms of heart failure (HF), which may require inotropic support. Levosimendan enhances the contractile response to intracellular calcium, and does not increase myocardial oxygen consumption [2]. Levosimendan also causes vasodilation by opening potassium channels in vascular smooth muscle cells in the arterial wall [2].
